JP2021521439A5 - - Google Patents

Info

Publication number
JP2021521439A5
JP2021521439A5 JP2020555862A JP2020555862A JP2021521439A5 JP 2021521439 A5 JP2021521439 A5 JP 2021521439A5 JP 2020555862 A JP2020555862 A JP 2020555862A JP 2020555862 A JP2020555862 A JP 2020555862A JP 2021521439 A5 JP2021521439 A5 JP 2021521439A5
Authority
JP
Japan
Prior art keywords
cancer
composition according
cytokine
composition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020555862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521439A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/027169 external-priority patent/WO2019200223A1/en
Publication of JP2021521439A publication Critical patent/JP2021521439A/ja
Publication of JP2021521439A5 publication Critical patent/JP2021521439A5/ja
Pending legal-status Critical Current

Links

JP2020555862A 2018-04-13 2019-04-12 がん血清バイオマーカーおよびその使用方法 Pending JP2021521439A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862657370P 2018-04-13 2018-04-13
US62/657,370 2018-04-13
US201862734133P 2018-09-20 2018-09-20
US62/734,133 2018-09-20
US201862756496P 2018-11-06 2018-11-06
US62/756,496 2018-11-06
PCT/US2019/027169 WO2019200223A1 (en) 2018-04-13 2019-04-12 Cancer serum biomarkers and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2021521439A JP2021521439A (ja) 2021-08-26
JP2021521439A5 true JP2021521439A5 (enExample) 2022-04-19

Family

ID=68164571

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555862A Pending JP2021521439A (ja) 2018-04-13 2019-04-12 がん血清バイオマーカーおよびその使用方法

Country Status (6)

Country Link
US (1) US20210025895A1 (enExample)
EP (1) EP3775877A4 (enExample)
JP (1) JP2021521439A (enExample)
CN (1) CN112005114A (enExample)
CA (1) CA3095331A1 (enExample)
WO (1) WO2019200223A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
EP3808748B1 (en) 2016-06-21 2026-05-20 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
US20210363590A1 (en) * 2018-05-21 2021-11-25 Nanostring Technologies, Inc. Molecular gene signatures and methods of using same
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法
WO2021263115A1 (en) * 2020-06-26 2021-12-30 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cancer, overcoming pd-1/pd-l1 blockade resistance, and determining resistance to checkpoint inhibitor treatment
JP2024505333A (ja) 2020-12-21 2024-02-06 フリーノム ホールディングス，インク． 結腸細胞増殖障害の早期検出のためのマーカー
US12523658B2 (en) * 2021-08-27 2026-01-13 The Board Of Regents Of The University Of Texas System Methods for the assessment of risk and treatments for liver cancers and lethal liver disease complications
CA3233049A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Lymphatic fluid for diagnostics
CN114859050B (zh) * 2022-05-30 2026-02-17 复旦大学附属肿瘤医院 三阴性乳腺癌免疫治疗疗效预测标志物ccl19的检测方法
CN117204817A (zh) * 2023-08-17 2023-12-12 北京肿瘤医院(北京大学肿瘤医院) 一种血管生成抑制剂给药控制方法、装置及存储介质

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6483705B2 (en) * 2001-03-19 2002-11-19 Harris Corporation Electronic module including a cooling substrate and related methods
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
MX2017007535A (es) * 2014-12-09 2017-08-10 Merck Sharp & Dohme Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1).
WO2016168133A1 (en) * 2015-04-17 2016-10-20 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
EP3405203A4 (en) * 2016-01-22 2019-07-24 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
US11337969B2 (en) * 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer

Similar Documents

Publication Publication Date Title
Kroemer et al. Immunosurveillance in clinical cancer management
Nabizadeh et al. The complement C3a receptor contributes to melanoma tumorigenesis by inhibiting neutrophil and CD4+ T cell responses
Waldner et al. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development
Rejeski et al. Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy
Bahig et al. Neutrophil count is associated with survival in localized prostate cancer
Xia et al. Plasma interleukin‐37 is elevated in patients with rheumatoid arthritis: its correlation with disease activity and Th1/Th2/Th17‐related cytokines
Ghanim et al. Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis
JP2021521439A (ja) がん血清バイオマーカーおよびその使用方法
Llosa et al. Interleukin-17 and type 17 helper T cells in cancer management and research
Krzystek-Korpacka et al. Elevated systemic interleukin-7 in patients with colorectal cancer and individuals at high risk of cancer: association with lymph node involvement and tumor location in the right colon
Chen et al. Chinese herbal medicine suppresses invasion-promoting capacity of cancer-associated fibroblasts in pancreatic cancer
Wang et al. Cytokine profiles and the relationship of disease severity in patients with psoriasis
Baracco et al. Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer
Wubetu et al. High STAT4 expression is a better prognostic indicator in patients with hepatocellular carcinoma after hepatectomy
Skipworth et al. Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer
Massari et al. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Singh et al. Idiopathic pulmonary fibrosis: where do we stand and how far to go
Wang et al. The role of IL-37 in gastrointestinal diseases
Yang et al. Liver metastasis of colorectal cancer: Mechanism and clinical therapy
Chen et al. Correlations between serum IL33 and tumor development: a meta-analysis
Remi et al. Pharmacological management of bronchorrhea in malignant disease: a systematic literature review
Falkensammer et al. C‐reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL‐6 in overall survival
Xing et al. Serum GDF15 level as predictive biomarker of clinical outcome in patients with unresectable hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy
Culcu et al. The effect of CEA/Albumin ratio in gastric cancer patient on prognostic factors
Liu et al. Water‐filtered infrared A radiation hyperthermia combined with immunotherapy for advanced gastrointestinal tumours